news
J&J accelerates clinical trial of investigational COVID-19 vaccine
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
List view / Grid view
Johnson & Johnson (J&J)
article
How can we develop more effective antidepressants?
Sergio Traversa, PharmD, from Relmada Therapeutics explains why NMDA antagonists may provide an answer for patients who do not respond to current antidepressant therapies.
news
FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
news
J&J says clinical trials for COVID-19 vaccine candidate will begin by September
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
news
Global collaboration formed to develop novel treatment regimens for TB
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
news
Biologics patent expiry to positively impact US pharma, says report
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
news
Johnson & Johnson “most valuable” pharma brand, says report
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
news
Top five pharma companies saw overall decline in Q3 2019
Research has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
news
J&J to provide 200,000 Ebola vaccine regimens to Rwanda
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
article
Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?
news
Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
news
J&J reach $20.4m settlement agreement over opioid trial
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
news
DRC announces plans to use second Ebola vaccine
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
news
J&J ordered to pay $572m to Oklahoma over opioid crisis
The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.
